Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. - Wikidata - awgldk - TriplyDB

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q45070082

about

Nonalcoholic fatty liver disease Non-alcoholic fatty liver disease: what the clinician needs to know.Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link Treatment of non-alcoholic fatty liver disease Pathophysiology guided treatment of nonalcoholic steatohepatitis Treatment of nonalcoholic steatohepatitis in adults: present and future Role of diet on non-alcoholic fatty liver disease: An updated narrative review Strategies to rescue steatotic livers before transplantation in clinical and experimental studies Nonalcoholic fatty liver disease: new treatments Review article: the metabolic syndrome and non-alcoholic fatty liver disease Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.Promising therapies for treatment of nonalcoholic steatohepatitis.Does pressure cause liver cirrhosis? The sinusoidal pressure hypothesis.Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.Non-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation.Role of NADPH oxidases in liver fibrosis.Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation.Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis Is there an effective therapy available for non-alcoholic fatty liver disease?Treatment options for nonalcoholic Fatty liver disease Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.Current status of therapy in nonalcoholic Fatty liver disease.Treatment of non-alcoholic fatty liver disease.Hypertension and fatty liver: guilty by association?Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population.Genetic determinants of hepatic steatosis in man.CORRELATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND FEATURES OF METABOLIC SYNDROME IN MORBIDLY OBESE PATIENTS IN THE PREOPERATIVE ASSESSMENT FOR BARIATRIC SURGERY.Effects of candesartan and propranolol combination therapy versus propranolol monotherapy in reducing portal hypertension.The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort.The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C.Non-alcoholic fatty liver disease: The diagnosis and management.Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease Pathogenesis and management issues for non-alcoholic fatty liver disease Treatment of idiopathic pulmonary fibrosis with losartan: a pilot project.Nonalcoholic fatty liver disease: a review.Recent concepts in non-alcoholic fatty liver disease.

P2860

Q24555779-8A454D8D-2E20-40E2-850C-FD1CCF4EB93F Q24563068-3EF11E4C-7BDD-4C3A-A09D-6964C2B37C33 Q24631619-16A4E897-8DBD-4887-8E59-997BBF447160 Q24655572-36A7F3CC-F03D-4334-AD04-8C28A04ACA6C Q26827117-8AA2846A-CC40-4B83-85F4-B1D525630E02 Q26852403-FF18F8C7-40DC-4306-BBDF-662DA6C288EB Q27000333-84655E23-DA66-44E1-84BA-4881A7F89ED6 Q27003912-B04C7C50-929B-4498-A337-882F14787B15 Q27021161-6FFABFA8-FB61-4A67-A5D5-8942806CAB86 Q28192695-759AAE3F-4CDB-4575-AEC8-5447A0B6E078 Q30235846-F33C8257-05D4-47C2-8E53-25D36E99A432 Q30248578-BF4543E1-2364-4EC9-9BEE-65A143D89E88 Q30365826-9288D1F3-7766-4579-9539-E3FB3617E55D Q30389752-65825E34-CFDD-415A-ACC9-65E2C796BD7E Q30401022-9255DA0A-672B-424E-8188-817FB95D70E4 Q33439253-E2A7211A-3AB2-4FA9-9D96-3A5E87AAA345 Q33574413-5EA9A0F8-5317-4037-93DF-977943320F05 Q33581421-D1052253-52D3-465A-895C-7FD73BEBB052 Q33632736-5666F719-752B-4206-9EE3-B77693F9F2C5 Q33755829-9CBAAAA7-50E0-4EC2-876F-406908DBE9D2 Q33788174-9DC223D7-EFD4-4D60-87CD-FC80C9587744 Q34076451-A7E2999D-B340-4B05-89B4-C43F2F00009F Q34156317-5072477E-ECC3-459E-98E3-CC4273149F17 Q34168532-D24A0BD8-3AF7-46ED-904D-645ADF0596DB Q34408961-DF63AF18-0EF6-4C46-95C3-D1EBF9FBB7B8 Q34592654-B8328812-8F8D-4B45-817D-0CEB1CB6AE08 Q34608817-6937067F-8595-411F-BEDA-1E833D2C6901 Q34618881-EA5F5B48-EE6C-45A8-9A82-00FE26F3DA3E Q34646183-0E2E5191-CC5E-4BD0-B144-B2D8F66BC3A1 Q34680490-5EE0DD92-955B-4705-906E-ECEE617DA437 Q34779763-6C25A1CC-AF5A-42CC-B68F-F9A10AF98B74 Q35124395-84572E6C-E4FC-4923-9259-55C246B69D26 Q35150772-E01ED05C-6C11-449D-A4FE-822DD5F98F74 Q35543956-1ABAB29A-8F02-45A5-B087-F8D9C8A14AA4 Q35674320-6F2F86BF-CCAD-4492-AD3C-867EA1512F81 Q36138443-FAE42469-AA5F-426B-8A5B-5C2B4B042C0D Q36179902-8872DC96-A2E9-429E-8FD9-60D5D9C62F17 Q36206673-3B4E942E-0764-45B3-A9B9-62D530DB1B9E Q36219675-2F57B730-8DF6-4AFC-A6E6-83805CAFB140 Q36234172-1195286A-9B62-4981-BEBE-DE44688E4167

P2860

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis.

http://www.wikidata.org/entity/Q45070082

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Therapeutic efficacy of an ang ...... nonalcoholic steatohepatitis.

@en

Therapeutic efficacy of an ang ...... nonalcoholic steatohepatitis.

@nl

type

label

Therapeutic efficacy of an ang ...... nonalcoholic steatohepatitis.

@en

Therapeutic efficacy of an ang ...... nonalcoholic steatohepatitis.

@nl

prefLabel

Therapeutic efficacy of an ang ...... nonalcoholic steatohepatitis.

@en

Therapeutic efficacy of an ang ...... nonalcoholic steatohepatitis.

@nl

P1433

Q45070082-1F4C37A5-FAEA-4E64-93C3-6DDFA5A7C031

P1476

Q45070082-12E74CEE-52A2-4673-B131-E15D3155F6E8

P2093

Q45070082-01406E32-96D3-4F93-92EE-4A9113FE394C

Q45070082-1C5937E9-AE2A-4CF7-9E13-208DF5E8C393

Q45070082-411F5974-F063-4A6B-938F-3E8DFA68CE4C

Q45070082-4AFE4A3A-7C7C-44DE-910A-5F42D7E4D029

Q45070082-50F5432B-0815-425C-A263-547D36E0BF0E

Q45070082-55E56362-5652-4A4C-B67E-CAF32B025706

Q45070082-60E20BEA-3D58-43AD-A722-38540325FA1C

Q45070082-6D587660-5C2A-4B3D-8897-C4CCEE883EBC

Q45070082-C595B3B6-6473-4302-A4D3-BAC49C20EA1B

Q45070082-E3AB7790-73DA-4626-BBAA-1BA50AEB9992

P304

Q45070082-BCB5A2E2-D304-4598-B89B-E0549CFC07C8

P31

Q45070082-0D10B6E4-437F-4001-8DD6-F74E45DD335A

P356

Q45070082-448D0FEC-D7E7-4348-AB03-427968886E4B

P407

Q45070082-716BB55F-F760-4D5C-BCEC-BA543A8FEF88

P433

Q45070082-2B1F89FF-0DC5-4463-B784-0197029B05F7

P478

Q45070082-ED0B8A31-BE17-4EC9-9172-2930C3A0EED1

P577

Q45070082-40DB9FDC-3535-472B-8334-D101D8CAE296

P5875

Q45070082-B24AF561-9422-4BF4-9D52-0C5ED4D9FA8E

P698

Q45070082-36EACF41-B6DC-4899-AFD3-07B6334BA48C

P921

Q45070082-D8CDA34E-88D0-4516-A52A-EEF5FBD76D10

P356

P1433

P1476

Therapeutic efficacy of an ang ...... nonalcoholic steatohepatitis.

@en

P2093

Kazunobu Aso

http://www.w3.org/2001/XMLSchema#string

Kimihide Nakamura

http://www.w3.org/2001/XMLSchema#string

Masakazu Haneda

http://www.w3.org/2001/XMLSchema#string

Masashi Yoneda

http://www.w3.org/2001/XMLSchema#string

Mituyoshi Okada

http://www.w3.org/2001/XMLSchema#string

Naoyuki Miyokawa

http://www.w3.org/2001/XMLSchema#string

Satoshi Okamoto

http://www.w3.org/2001/XMLSchema#string

Shiro Yokohama

http://www.w3.org/2001/XMLSchema#string

Takenao Hasegawa

http://www.w3.org/2001/XMLSchema#string

Yoshihiko Tokusashi

http://www.w3.org/2001/XMLSchema#string

P304

1222-1225

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.20420

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2004-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8333114

http://www.w3.org/2001/XMLSchema#string

P698

15382153

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis